Tom van der Poll - Publications#

Web of Science Report (01.2023: 1,043 publications 1085, cited 72,343 times, H-index 120
Google Scholar Report (01.2023): 109,170 citations (54,057 since 2018); H-index 143.

10 selected publications (most recent 5 years):

1. Peters-Sengers H., Butler J.M., Uhel F., Schultz M.J., Bonten M.J., Cremer O.L., Scicluna B.P., van Vught L.A., van der Poll T.; MARS consortium. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 2022; 48: 92-102

2. Van der Poll T., Shankar-Hari M., Wiersinga W.J. The immunology of sepsis. Immunity 2021; 54: 2450-2464.

3. Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nature Rev Dis Primers 2021; 7: 25.

4. Uhel F., Peters-Sengers H., Falahi F., Scicluna B.P., van Vught L.A., Bonten M.J., Cremer O.L., Schultz M.J., van der Poll T; MARS consortium. Mortality and host response aberrations associated with transient and persistent acute kidney injury in critically ill patients with sepsis: a prospective cohort study. Intensive Care Med. 2020; 46: 1576-1589.

5. van der Poll T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: another negative sepsis trial? JAMA 2019; 321:1978-1980.

6. Claushuis T.A.M., de Vos A.F., Nieswandt B., Boon L., Roelofs J.J.T.H., de Boer O.J., van 't Veer C., van der Poll T. Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria. Blood 2018; 131: 864-876

7. Scicluna B.P., van Vught L.A., Zwinderman A.H., Wiewel M.A., Davenport E.E., Burnham K.L., Nürnberg P., Schultz M.J., Horn J., Cremer O.L., Bonten M.J., Hinds C.J., Wong H.R., Knight J.C., van der Poll T. Classification of sepsis patients as blood genomic endotypes: a prospective cohort study. Lancet Respir. Med. 2017; 5: 816-826.

8. Van der Poll T., van de Veerdonk F.L., Scicluna B.S., Netea M.G. The immunopathology of sepsis and potential therapeutic targets. Nature Reviews Immunology 2017; 17(7):407-420.

9. Van Vught L.A., Klein Klouwenberg P.M.C., Spitoni C., Scicluna B.P., Wiewel M.A., Horn J., Schultz M.J., Nürnberg P., Bonten M.J.M, Cremer O.L., van der Poll T; on behalf of the MARS consortium. Incidence, risk factors and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016; 315: 1469-79.

10. Cheng S.C., Scicluna B.P., Arts R.J.W., Gresnigt M.S., Lachmandas E., Giamarellos-Bourboulis E.J., Kox M., Manjeri G.R., Wagenaars J., Cremer O.L., Leentjens J., van der Meer A.J., van de Veerdonk F., Bonten M.J., Schultz M.J., Willems P., Pickkers P., Joosten L.A.B., van der Poll T.*, Netea M.G.* (*shared senior authorship). Broad defects in energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nature Immunology 2016; 17: 406-13.